Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02994381
Recruitment Status : Completed
First Posted : December 15, 2016
Last Update Posted : January 27, 2017
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:

This will be an open-label, non-randomized, single oral dose study in healthy male subjects.

All subjects will receive a single oral dose of 10 mL of [14C]-RPC1063 Solution (0.1 mg/mL), containing NMT 1.3 MBq (37 μCi) 14C.


Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: RPC1063 Phase 1

Detailed Description:
Subjects will be screened for eligibility to participate in the study up to 28 days before dosing. Subjects will be admitted to the clinical unit on the morning of Day -1 prior to IMP administration. Subjects will be dosed on the morning of Day 1 following a standard breakfast, and will remain resident in the clinic until up to 168 h after dosing. It is planned that subjects will be released as a group when all subjects have achieved a mass balance cumulative recovery of >90% or if <1% of the dose administered has been collected in urine and faeces within 2 separate, consecutive 24 h periods. This may be earlier than 168 h post-dose but no sooner than 96 h post-dose. In this case, collection of all samples (blood, urine and faeces) will be stopped and the subjects will undergo discharge assessments. If this criteria has not been met by all subjects on Day 8, home collections of urine and faeces may be requested at the discretion of the investigator for individual subjects. A follow-up phone call will take place 5 to 10 days after discharge.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults
Study Start Date : October 2016
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016

Arm Intervention/treatment
Experimental: [14C]-RPC1063 Solution (0.1 g/mL)
1 mg; 10 mL [14C]-RPC1063 HCl oral dose containing NMT 1.3 MBq (37 μCi) 14C
Drug: RPC1063



Primary Outcome Measures :
  1. Percentage of elimination of [14C]-RPC1063 [ Time Frame: Up to 4 weeks ]
    Total recovery of radioactivity in urine and feces expressed as a percentage of total radioactive dose in each 24 h interval and cumulatively

  2. Pharmacokinetic- amount of drug excreted [ Time Frame: Up to 4 weeks ]
    Cumulative amount of drug excreted unchanged in the drug in urine


Secondary Outcome Measures :
  1. Pharmacokinetic- Cmax [ Time Frame: Up to 8 days ]
    Maximum observed concentration

  2. Pharmacokinetic- Tmax [ Time Frame: Up to 8 days ]
    Time at maximum observed concentration

  3. Pharmacokinetic- AUC0-last [ Time Frame: Up to 8 days ]
    Area under the curve from 0 time to last measurable concentration

  4. Pharmacokinetic- AUC0-inf [ Time Frame: Up to 8 days ]
    Area under the curve from 0 time extrapolated to infinity

  5. Pharmacokinetic- λz [ Time Frame: Up to 8 days ]
    Elimination rate constant

  6. Pharmacokinetic- t1/2 [ Time Frame: Up to 8 days ]
    Terminal elimination half-life

  7. Pharmacokinetic- CL/F [ Time Frame: Up to 8 days ]
    Clearance, the apparent volume cleared of parent drug per unit time after extravascular administration

  8. Pharmacokinetic- Vz/F [ Time Frame: Up to 8 days ]
    The apparent volume of distribution after extravascular administration

  9. Pharmacokinetic- CLr [ Time Frame: Up to 8 days ]
    Renal clearance

  10. Adverse Events (AEs) [ Time Frame: Approximately 2 months ]
    Number of participants with adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject is male
  2. Subject is 30 to 65 years of age
  3. Subject has a body weight of at least 50 kg; body mass index (BMI) of 18.0 to 32.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator
  4. Subject is willing and able to communicate and participate in the whole study
  5. Subject has regular bowel movements (average stool production ≥1 and ≤3 stools per day)
  6. Subject has suitable veins for multiple cannulation as assessed by the investigator at screening
  7. Subject is able to comprehend the informed consent form, provide written informed consent, and able to comply with requirements of the study.
  8. Subject agrees to use an adequate method of contraception

Exclusion Criteria:

  1. Subject has received any investigational medicinal product (IMP) in a clinical research study within the previous 3 months
  2. Subject is a study site employee or an immediate family member of a study site or sponsor employee
  3. Subject has a history of any drug or alcohol abuse in the past 2 years
  4. Subject has regular alcohol consumption of >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  5. Subject is a current smoker or has smoked within the last 12 months; including cigarettes, e-cigarettes and nicotine replacement products. Positive cotinine test result at screening and admission
  6. Subject has radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
  7. Subjects has been enrolled in an absorption, distribution, metabolism and elimination (ADME) study in the last 12 months
  8. Subject has clinically significant abnormal biochemistry or haematology as judged by the investigator
  9. Subject has positive drugs of abuse test result
  10. Subject has positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
  11. Subject has evidence of renal impairment at screening and admission, as indicated by an estimated creatinine clearance (CLcr) of <90 mL/min using the Cockcroft-Gault equation
  12. Subject has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) concentration >1.25 × the ULN at screening
  13. Subject has history of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the investigator
  14. Subject has had serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
  15. Subject has presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active
  16. Subject has donated or lost greater than 400 mL of blood within the previous 3 months
  17. Subject is taking, or has taken, any prescribed or over-the-counter drug (other than 2 g per 24 h paracetamol) dietary or herbal remedies within 14 days before IMP administration, or has taken St. John's wort within 28 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor.
  18. Subject fails to satisfy the investigator of fitness to participate for any other reason

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02994381


Locations
Layout table for location information
United Kingdom
Quotient Clinical
Nottingham, United Kingdom, NG11 6JS
Sponsors and Collaborators
Celgene
Investigators
Layout table for investigator information
Study Director: Jonathan Tran, Pharm.D Celgene Corporation
Layout table for additonal information
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT02994381    
Other Study ID Numbers: RPC01-1909
First Posted: December 15, 2016    Key Record Dates
Last Update Posted: January 27, 2017
Last Verified: January 2017
Keywords provided by Celgene:
Healthy Male Adults
14C
RPC1063